 Home > Active Ingredient News > Antitumor Therapy > Kangfang Bio-PD-1/VEGF dual antibody initiates multiple clinical studies

Kangfang Bio-PD-1/VEGF dual antibody initiates multiple clinical studies

 Last Update: 2021-05-23
 Source: Internet
 Author: User

Tags

small text art

small cell lymphoma

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Source: Guanlan Pharmaceutical

On May 12, Kangfang Bio announced that the company’s core self-developed new tumor immunotherapy drug AK112 (PD-1/VEGF bispecific antibody) has carried out dose ramping and extended phase 1 clinical trials in China, Australia and other countries.

Screenshot source: Chinadrugtrials

It is reported that AK112 is designed based on Kangfang's unique TETRABODY technology, which can block the binding of PD-1 to PD-L1 and PD-L2, and at the same time block the binding of VEGF to VEGF receptors.

Note: The original text has been deleted

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

​Kangfang Bio-PD-1/VEGF dual antibody initiates multiple clinical studies

Kangfang Bio-PD-1/VEGF dual antibody initiates multiple clinical studies